Literature DB >> 10617169

Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea.

R B Berry1, E M Yamaura, K Gill, C Reist.   

Abstract

STUDY
OBJECTIVE: To determine the acute effects of paroxetine on genioglossus activity during NREM sleep.
DESIGN: A single dose of Paroxetine (40 mg) or placebo was administered four hours before bedtime on nights separated by one week in a double blind randomized crossover manner. The moving time average of genioglossus muscle activity (EMGgg) expressed as a percentage of maximum was measured using a mouthpiece electrode customized for each subject. The peak inspiratory and tonic values of EMGgg and the corresponding esophageal pressure deflections (DP) during the last three occluded breaths of obstructive apneas during NREM sleep were analyzed.
SETTING: NA. PARTICIPANTS: 8 adult men with severe obstructive sleep apnea (OSA).
INTERVENTIONS: NA. MEASUREMENTS AND
RESULTS: Paroxetine increased the peak inspiratory EMGgg (29.8+/-2.4 (SE) versus 24.4+/-2.7 % max, p<0.05) and peak EMGgg/DP ratio (0.78+/-0.12 versus 0.65+/-0.11 % max/cm H2O, p<0.01) but not the tonic EMGgg (11.6+/-0.9 versus 9.8+/-0.7 % max) nor the DP (39.4+/-2.2 versus 38.2+/-2.8 cm H2O). Linear regression analysis of the peak inspiratory EMGgg versus DP relationship showed that paroxetine increased the slope (0.62+/-0.11 versus 0.49+/-0.09 % max/cm H2O, p<0.01). However, the apnea + hypopnea index (paroxetine: 75.2+/-5.5 versus placebo: 73.7+/-6.9 events/hour) did not differ.
CONCLUSIONS: Paroxetine augmented peak inspiratory genioglossus activity during NREM sleep but this effect was not sufficient to decrease the frequency of obstructive apnea in this group with severe OSA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10617169     DOI: 10.1093/sleep/22.8.1087

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  23 in total

1.  The effect of increased genioglossus activity and end-expiratory lung volume on pharyngeal collapse.

Authors:  Amy S Jordan; David P White; Robert L Owens; Danny J Eckert; Shilpa Rahangdale; Susie Yim-Yeh; Atul Malhotra
Journal:  J Appl Physiol (1985)       Date:  2010-05-27

2.  The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.

Authors:  Luigi Taranto-Montemurro; Ludovico Messineo; Scott A Sands; Ali Azarbarzin; Melania Marques; Bradley A Edwards; Danny J Eckert; David P White; Andrew Wellman
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

Review 3.  Physiology in medicine: obstructive sleep apnea pathogenesis and treatment--considerations beyond airway anatomy.

Authors:  Jerome A Dempsey; Ailiang Xie; David S Patz; David Wang
Journal:  J Appl Physiol (1985)       Date:  2013-11-07

4.  Differential respiratory control of the upper airway and diaphragm muscles induced by 5-HT1A receptor ligands.

Authors:  Stephane Besnard; Hanan Khemiri; Fabienne Masse; Pierre Denise; Marion Verdaguer; Christian Gestreau
Journal:  Sleep Breath       Date:  2011-01-09       Impact factor: 2.816

Review 5.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

6.  Injection of L-glutamate into the insular cortex produces sleep apnea and serotonin reduction in rats.

Authors:  Li Cui; Jing-Hua Wang; Min Wang; Min Huang; Chun-Yong Wang; Huan Xia; Jian-guo Xu; Ming-Xian Li; Shao Wang
Journal:  Sleep Breath       Date:  2011-09-27       Impact factor: 2.816

Review 7.  The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review.

Authors:  Afshin Shirani; Sergio Paradiso; Mark Eric Dyken
Journal:  Sleep Med       Date:  2011-06       Impact factor: 3.492

Review 8.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

9.  Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep-related breathing disorders.

Authors:  Bin Zhang; Yanli Hao; Fujun Jia; Xueli Li; Yi Tang; Huirong Zheng; Wuhan Liu
Journal:  Sleep Breath       Date:  2015-03-11       Impact factor: 2.816

Review 10.  Potential therapeutic targets in obstructive sleep apnoea.

Authors:  Julian P Saboisky; Nancy L Chamberlin; Atul Malhotra
Journal:  Expert Opin Ther Targets       Date:  2009-07       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.